As co-founder and Managing Director, Neal focuses on advising and facilitating superior decision-making in LCM and brand strategy. He supports pipeline, in-line and established brand planning with a focus on competitive simulations, late-stage LCM and portfolio strategy.
Prior to establishing Align Strategy and its predecessor Hansen Strategy, Neal was the Global Director of Healthcare Consulting within the Informa Group, leading both Phasic Strategy and Datamonitor Healthcare Consulting. Previously, Neal was the European Head of Consulting at Wood Mackenzie.
Neal co-authored “Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand.” He is an expert trainer in LCM and Competitive Strategy, delivering both in-house and public courses (e.g. CELforPharma and EphMRA). Neal holds an MA and a PhD from the University of Cambridge.
One of Align Strategy’s two founders and Managing Directors, Christine has spent over 15 years as a consultant working strictly within the pharmaceutical and biotechnology industries. Her expertise lies in helping portfolio and brand teams at top-tier pharmaceutical companies in Europe and the US to develop and pressure-test strategies in the context of a dynamic and changing market environment. Christine has extensive experience leading scenario planning, competitor/stakeholder simulations and other strategic engagements across various therapeutic areas.
Previously, Christine was Director of Phasic Strategy and Head of Strategic Planning within Wood Mackenzie’s Life Sciences consulting practice; earlier in her career she held consulting positions in the Life Sciences groups at Stanford Research Institute (SRI) Consulting and Beacon Hill Technologies. She received a BA in Economics from Tufts University.
Andrew is a Director at Align Strategy. He partners with clients to develop, manage, design, and ensure effective delivery of a range of strategic projects at the brand and franchise level across a broad range of therapeutic areas. Andrew has significant experience of working at a global, regional and affiliate level.
With over 18 years of experience in the pharmaceutical industry working for Phasic Strategy, Datamonitor, Wood Mackenzie and Pfizer, Andrew understands what makes a strategic project successful – listening carefully to clients and working collaboratively and flexibly.
Andrew holds two degrees from the University of Glasgow – a PhD in Chemistry (in collaboration with the former Glaxo Wellcome) and a BSc (Hons) in Medicinal Chemistry.
Building on 15 years of experience consulting in the healthcare industry, Nicola’s expertise encompasses the design and delivery of the spectrum of strategic planning engagements for pharmaceutical clients. As a Director at Align Strategy, Nicola focuses on franchise- and brand-level strategy definition, bringing a deep understanding of the issues facing pharma teams and a proven ability to develop flexible solutions to deliver to project objectives.
Nicola joined Align from Phasic Strategy and was previously part of the Pharma and Biotech Consulting and Analysis teams at Wood Mackenzie, based in both their UK and US offices.
Nicola holds a PhD in Molecular Genetics from the University of Edinburgh (partly sponsored by the former SmithKline Beecham) and a MA (Hons) in Natural Sciences from the University of Cambridge.
Jing’s area of expertise lies in brand-level strategy optimisation. Jing has worked in the pharmaceutical sector for over ten years and has experience working with pharmaceutical companies in the delivery of a range of projects including competitor simulations, facilitated decision-making and situational analyses.
Previously, Jing was a senior member of the Phasic Strategy team, based in both London and Boston offices. She also worked as an Analyst at PharmaVentures.
She holds a PhD in Clinical Pharmacology from the University of Cambridge and a BSc (Hons) in Biochemistry from the University of Manchester.
Ellen has over 20 years of experience in pharmaceuticals, both in the industry and as a consultant. For the past 12 years, Ellen has assisted companies globally in corporate and business unit strategy consulting. She has worked across many biopharmaceutical and technology segments and has assisted clients with issues such as strategic opportunity evaluations, portfolio prioritization, new product planning, strategic partnering, in- and out-licensing. Her work has supported the capital raises of dozens of companies totalling hundreds of millions of dollars as well as the successful sale of small biotech companies to large pharma players.
Prior to joining Align, Ellen was Director of Pharma Consulting at Informa Business Intelligence (formerly Datamonitor). She started her career with roles in Marketing, Corporate Development, and New Product Planning as part of the Neuroscience business unit at Elan Pharmaceuticals.
Ellen earned a Master of Business Administration from the Anderson School at the University of California, Los Angeles (UCLA) and her Bachelor of Science in Mathematics from Chestnut Hill College.